Vertex Pharmaceuticals

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$3,227,100
$3,076,400
$2,964,700
$2,770,200
Gross Profit
2,761,100
2,661,600
2,557,200
2,407,200
EBITDA
1,353,500
1,356,100
1,338,400
781,800
EBIT
1,300,400
1,302,100
1,286,700
733,400
Net Income
1,191,100
1,082,900
1,032,900
646,300
Net Change In Cash
3,227,100
3,076,400
2,964,700
2,770,200
Free Cash Flow
348,600
1,139,600
927,400
778,200
Cash
5,087,800
4,939,600
4,972,200
4,674,700
Basic Shares
256,100
257,600
258,900
259,500

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$12,074,600
$11,020,100
$9,869,200
$8,930,700
Gross Profit
10,267,500
9,489,600
8,607,000
7,850,400
EBITDA
4,967,900
486,300
4,605,200
4,435,500
EBIT
4,760,700
280,500
4,423,900
4,287,200
Net Income
3,953,200
-535,600
3,619,600
3,322,000
Net Change In Cash
12,074,600
11,020,100
9,869,200
8,930,700
Cost of Revenue
3,741,100
Free Cash Flow
3,193,800
-790,300
3,278,900
3,925,200
Cash
5,087,800
4,569,600
10,369,100
10,504,000
Basic Shares
258,000
257,900
260,500
259,100

Earnings Calls

QuarterEPS
2025-12-31
$5.03
2025-09-30
$4.80
2025-06-30
$4.52
2025-03-31
$4.06